Status:
COMPLETED
Effect of Vitamin D on Everolimus Trough Concentrations Among Heart Transplanted Patients
Lead Sponsor:
Sheba Medical Center
Conditions:
Vitamin D Deficiency
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Vitamin D is part of the regular treatment regimen among patients after heart transplantation. Due to potential drug-drug interaction between vitamin D and everolmus, these patients are in increased r...
Detailed Description
post heart transplantation patients treated with everolimus will be screened for vitamin D levels. Patients defined as deficient will be treated with vitamin D with close and intensive monitoring ever...
Eligibility Criteria
Inclusion
- Heart transplanted patients treated with everolimus
Exclusion
- \-
Key Trial Info
Start Date :
July 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2019
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03403647
Start Date
July 15 2018
End Date
April 10 2019
Last Update
April 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel